Related Experiment Videos
Chronic hepatitis C: common questions, practical answers
Insights
Hepatitis C virus (HCV) treatment with interferon and ribavirin offers over 30% chance of sustained viral clearance. Primary care physicians are crucial for diagnosing HCV and guiding patients on antiviral therapy risks and benefits.
Area of Science:
- Hepatology
- Infectious Diseases
- Gastroenterology
Background:
- Hepatitis C virus (HCV) is a leading cause of chronic liver disease in the U.S.
- Recent advances include combination therapy with interferon and ribavirin.
- HCV infection poses a significant public health challenge.
Purpose of the Study:
- To address common questions faced by primary care physicians regarding chronic HCV infections.
- To provide evidence-based guidance on HCV diagnosis and management.
- To inform primary care providers about the utility of antiviral therapies.
Main Methods:
- Elicited primary care physician questions via email and phone interviews.
- Conducted computerized literature searches of MEDLINE database.
- Consulted expert opinion for comprehensive answers.
Main Results:
- Combination therapy yields >30% chance of normalized transaminase levels and undetectable viral load.
- Treatment is costly and may have side effects.
- Long-term impact on liver failure and hepatocellular carcinoma risk is promising but undetermined.
Conclusions:
- Primary care physicians are vital for HCV diagnosis and initial patient evaluation.
- Understanding diagnostic testing and antiviral therapy is key for effective patient screening and counseling.
- Enhanced provider knowledge improves HCV patient care outcomes.
Background:
The hepatitis C virus (HCV) is the most common cause of chronic liver disease in the United States. Dramatic advances have been made recently in the treatment of this potentially life-threatening infection by using a combination interferon and ribavirin therapy.
Methods:
The most common questions regarding chronic HCV infections that occur in the course of clinical practice of primary care physicians were elicited through e-mail and telephone interviews. To answer these questions, computerized literature searches of the MEDLINE database were performed and expert opinion was sought.
Results:
For many patients with HCV who are treated with combination therapy, there is now a greater than 30% chance of achieving long-term normalization of transaminase levels and the loss of detectable viral load. Treatment is expensive, however, and can be difficult to tolerate. The effect of treatment on the risk of progression to liver failure and hepatocellular carcinoma is promising but has not yet been determined.
Conclusions:
Primary care physicians play an important role in the diagnosis and initial workup of patients with HCV. By understanding the correct use of HCV diagnostic testing and the risks and benefits of antiviral therapy, providers will be better equipped to screen and counsel their patients infected with HCV.